4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/343 (2006.01) A61P 7/02 (2006.01) C07C 251/60 (2006.01) C07D 307/81 (2006.01)

Patent

CA 2538574

The present invention relates to benzofuryl-oximes of formula (I) or a pharmaceutically acceptable salt or ester form thereof wherein R1 is a direct bond to A, C1-C4 alkylene, or -O-C1-C4 alkylene; R2 and R3 are, independently hydrogen, halogen, C1-C4 alkyl, C1-C3 perfluoroalkyl, -O-C1-C3 perfluoroalkyl, C1-C3 alkoxy, -OH, -NH2, -NO2, -O(CH2)p-aryl, -O(CH2)P-heteroaryl, aryl, heteroaryl, -NH(CH2)P-aryl, -NH(CH2)P-heteroaryl, -NH(CO)-aryl, NH(CO)- heteroaryl, -O(CO)-aryl, O(CO)-heteroaryl, -NH(CO)-CH=CH-aryl, or -NH(CO)- CH=CH-heteroaryl; p is an integer from 0-6; R4 is hydrogen, C1-C8 alkyl, or C3- C6 cycloalkyl; A is -COOH or an acid mimic; X is C1-C8 alkylène, C3-C6 cycloalkylene, -(CH2)mO-, or -(CH2)mNH-; m is an integer from 1-6; and R5 is hydrogen, C1-C8 alkyl, C3-C6 alkyl, C3-C6 cycloalkyl, -CH2-C3-C6 cycloalkyl, heteroaryl, -CH2-heteroaryl, aryl or benzyl; R6 and R7 are independently, hydrogen, halogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, -O-C1-C6 perfluoroalkyl, C1-C6 alkoxy, _OH, -NH2, -NO2, -O(CH2)n-aryl, -O(CH2)n-heteroaryl, aryl, or heteroaryl; and n is an integer from 0-6, wherein the alkyl, cycloalkyl, aryl and heteroaryl groups are each optionally substituted by one or more substituents. The present compounds are PAI-1 inhibitors for the treatment e.g of impairment of the fibrinolytic system, thrombosis or cardiovascular diseases.

La présente invention concerne des benzofuryl-oximes de formule (I) ou un sel pharmaceutiquement acceptable ou une forme estérique desdits composés. Dans ladite formule, R¿1? est directement lié à A, alkylène C¿1?-C¿4? ou alkylène -O-C¿1?-C¿4?; R¿2? et R¿3? sont, indépendamment, hydrogène, halogène, alkyle C¿1?-C¿4?, perfluoroalkyle C¿1?-C¿3? perfluoroalkyle, perfluoroalkyle -O-C¿1?-C¿3?, alcoxy C¿1?-C¿3?, OH, -NH¿2?, -NO¿2?, -O(CH¿2?)¿p?-aryle, -O(CH¿2?)<SB>P</SB>-hétéroaryle, aryle, hétéroaryle, -NH(CH¿2?)<SB>P</SB>-aryle, -NH(CH¿2?)<SB>P</SB>-hétéroaryle, -NH(CO)-aryle, NH(CO)-hétéroaryle, -O(CO)-aryle, O(CO)-hétéroaryle, -NH(CO)-CH=CH-aryle ou -NH(CO)-CH=CH-hétéroaryle; p est un entier compris entre 0 et 6; R¿4? est hydrogène, alkyle C¿1?-C¿8? ou cycloalkyle C¿3?-C¿6?; A est -COOH ou un analogue de l'acide; X est alkylène C¿1?-C¿8?, cycloalkylène C¿3?-C¿6?, -(CH¿2?)¿m?O- ou -CH¿2?)¿m?NH-; m est un entier compris entre 0 et 6; et R¿5? est hydrogène, alkyle C¿1?-C¿8?, alkyle C¿3?-C¿6?, cycloalkyle C¿3?-C¿6?, cycloalkyle -CH¿2?-C¿3?-C¿6?, hétéroaryle, -CH¿2?-hétéroaryle, aryle ou benzyle; R¿6? et R¿7? sont, indépendamment, hydrogène, halogène, alkyle C¿1?-C¿6?, perfluoroalkyle C¿1?-C¿6?, perfluoroalkyle -O-C¿1?-C¿6?, alcoxy C¿1?-C¿6?, -OH, -NH¿2?, -NO?2¿, -O(CH¿2?)¿n?-aryle, -O(CH¿2?)¿n?-hétéroaryle, aryle ou hétéroaryle; et n est un entier compris entre 0 et 6; les groupes alkyle, cycloalkyle, aryle et hétéroaryle étant chacun éventuellement susbstitués par un ou plusieurs susbstituants. Les composés de l'invention sont des inhibiteurs de PAI-1 destinés au traitement, par exemple, d'une déficience du système fibrinolytique, de la thrombose ou de maladies cardiovasculaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(1-benzofuran-3-yl-methylideneaminoxy.propoxy))-benzoic... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1546958

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.